Low dose metronomic oral cyclophosphamide for hormone. - NCBI
J Urol. 2007 Jun;17762136-40; discussion 2140. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer a phase II study. Low-dose metronomic oral cyclophosphamide plus prednisone for castration resistant prostate cancer CRPC A retrospective study. Add to Collection. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. Gebbia V1, Boussen H.
Oral metronomic cyclophosphamide with and without methotrexate.
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer A Trial of the California, Chicago, and. Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer a case report of extraordinarily prolonged.
This led to the concept of metronomic chemotherapy giving patients. It has been proposed that the oral drugs cyclophosphamide and methotrexate be used for. Dec 13, 2014. Metronomic oral cyclophosphamide MOC in the salvage therapy of heavily treated recurrent ovarian cancer patients a retrospective.